Results 1 to 10 of 10
Page 1 of 1
TypeTitleAuthor(s)YearViews
The neglected hepatitis C virus genotypes 4, 5 and 6: An international consensus reportAntaki, N; Craxi, A; Kamal, S; Moucari, R; Van Der Merwe, S; Haffar, S; Gadano, A; Zein, N; Lai, CL; Pawlotsky, J; Heathcote, EJ; Dusheiko, G; Marcellin, P201081
 
2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis BLiaw, Y; Gane, E; Leung, N; Zeuzem, S; Wang, Y; Lai, CL; Heathcote, EJ; Manns, M; Bzowej, N; Niu, J; Han, S; Hwang, SG; Cakaloglu, Y; Tong, MJ; Papatheodoridis, G; Chen, Y; Brown, NA; Albanis, E; Galil, K; Naoumov, NV20091,845
 
Treatment of hepatitis B e antigen-positive chronic hepatitis with telbivudine or adefovir: A randomized trialChan, HLY; Heathcote, EJ; Marcellin, P; Lai, CL; Cho, M; Moon, YM; Chao, YC; Myers, RP; Minuk, GY; Jeffers, L; Sievert, W; Bzowej, N; Harb, G; Kaiser, R; Qiao, XJ; Brown, NA; Crawford, D; Lim, SG; Chutaputti, A; Poynard, T2007145
 
Telbivudine versus lamivudine in patients with chronic hepatitis BLai, CL; Gane, E; Liaw, YF; Hsu, CW; Thongsawat, S; Wang, Y; Chen, Y; Heathcote, EJ; Rasenack, J; Bzowej, N; Naoumov, NV; Di Bisceglie, AM; Zeuzem, S; Moon, YM; Goodman, Z; Chao, G; Constance, BF; Brown, NA2007257
 
A Randomized Trial of Telbivudine (LdT) vs Adefovir for HBeAg-positive Chronic Hepatitis B: Final Week 52 resultsBzowej, N; Chan, HLY; Lai, CL; Cho, M; Moon, YM; Chao, YC; Heathcote, EJ; Myers, R; Minuk, G; Marcellin, P; Jeffers, L; Sievert, W; Kaiser, R; Harb, G; Chao, GC; Brown, NA2006164
 
A Randomized Trial of Telbivudine (LdT) vs Adefovir for HBeAg-positive Chronic Hepatitis B: Results of the Primary Week 24 AnalysisHeathcote, EJ; Chan, HL; Cho, M; Lai, CL; Moon, YM; Chao, YC; Myers, R; Minuk, G; Marcellin, P; Jeffers, L; Sievert, W; Kaiser, R; Chao, G; Brown, N2006110
 
Effect of core promoter/precore mutation pattern and early virologic response on efficacy outcomes with telbivudine in HBeAg-negative chronic hepatitis BNaoumov, N; Lai, CL; Gane, E; Liaw, YF; Thongsawat, S; Wang, YM; Heathcote, EJ; Rasenack, J; Bzowej, N; Chao, G; Brown, N200699
 
Telbivudine Globe Trial: Maximal Early HBV Suppression is Predictive of Optimal Two-year Efficacy in Nucleoside-treated Hepatitis B PatientsDiBisceglie A, A; Lai, CL; Gane, E; Chen, YC; Thongsawat, S; Wang, YM; Chen, YG; Heathcote, EJ; Zeuzem, S; Rasenack, J; Bzowej, N; Han, SH; Naoumov, N; Hwang, SG; Lim, SG; Chao, GC; Fielman, BA; Brown, NA; Study Group The GLOBE,2006181
 
Two-year Results from the Globe Trial in Patients with Hepatitis B: Greater Clinical and Antiviral Efficacy for Telbivudine (LdT) vs LamivudineLai, CL; Gane, E; Hsu, CW; Thongsawat, S; Wang, YM; Chen, YG; Heathcote, EJ; Rasenack, J; Bzowej, N; Naoumov, N; Zeuzem, S; Di Bisceglie, A; Chao, GC; Barbara, A; Constance, F; Brown, NA; Study Group The GLOBE.,2006258
 
Long-Term Safety of Lamivudine Treatment in Patients with Chronic Hepatitis BLok, ASF; Lai, CL; Leung, N; Yao, GB; Cui, ZY; Schiff, ER; Dienstag, JL; Heathcote, EJ; Little, NR; Griffiths, DA; Gardner, SD; Castiglia, M2003147
 
Page 1 of 1
Export Records
Step 1: Select content and export format
  • Citation only
Step 2: Select export method
  • Download